Provider Review — May 2026
Physician-Led GLP-1 & GIP-GLP-1 Weight Loss — All-Inclusive Pricing
Always confirm current pricing, availability, and terms directly with Enhance MD before enrolling — program details change frequently across all GLP-1 platforms.
Enhance MD has built its reputation in the GLP-1 telehealth market on a single principle: physician leadership at every step of the patient journey. While many telehealth platforms have optimized their intake processes to minimize human involvement and accelerate enrollment, Enhance MD has taken the opposite approach — keeping licensed physicians at the center of every prescription decision, every dosing adjustment, and every patient interaction.
This philosophy translates into a measurably different patient experience. Where some platforms operate more like prescription delivery services with a brief physician review bolted on, Enhance MD functions as a genuine physician-led weight loss program that happens to operate through a telehealth model. The difference matters both clinically and in terms of patient outcomes.
Their coverage of both GLP-1 and GIP-GLP-1 medications — the two primary classes of injectable weight loss pharmacotherapy currently available — gives Enhance MD patients access to the full spectrum of options. A physician can assess which medication class is most appropriate for a specific patient's metabolic profile rather than defaulting to one option regardless of individual circumstances.
Understanding the medications Enhance MD prescribes helps patients make more informed enrollment decisions. GLP-1 medications — glucagon-like peptide-1 receptor agonists — work by mimicking a naturally occurring hormone that regulates appetite, slows gastric emptying, and stimulates insulin release in response to food intake. The result is reduced hunger, earlier satiety, and lower overall caloric intake over time.
GIP-GLP-1 dual agonists target both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor simultaneously. Clinical trial data — specifically the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 — demonstrated average body weight reductions of approximately 20% over 72 weeks for tirzepatide, compared to approximately 15% for semaglutide in the STEP-1 trial. Individual results vary significantly based on starting weight, adherence, diet, exercise, and individual metabolic response.
Both medication classes are administered as weekly subcutaneous injections and require a gradual dose escalation protocol — typically starting at a low dose and increasing every four weeks until the target maintenance dose is reached. This escalation process is designed to minimize side effects including nausea, which is the most commonly reported adverse event.
One of Enhance MD's most significant differentiators is their inclusion of comprehensive lab testing in the program. This matters for several important reasons that patients should understand before comparing programs on price alone.
Baseline laboratory work before starting a GLP-1 medication serves multiple clinical purposes. It establishes a metabolic baseline against which treatment response can be measured. It screens for contraindications — GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2. Lab work can also identify conditions like hypothyroidism that may interfere with weight loss outcomes if left untreated. And it provides the treating physician with the data needed to make a personalized medication recommendation rather than a generic one.
Many competing telehealth platforms skip baseline labs entirely to reduce cost and friction. This is an understandable business decision but a clinical shortcut. Enhance MD's inclusion of lab testing reflects a standard of care closer to what a patient would receive from an in-person obesity medicine specialist.
Enhance MD's program is designed for adults who meet standard GLP-1 eligibility criteria. Generally this means a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, hypertension, hyperlipidemia, or obstructive sleep apnea. A licensed physician makes the final eligibility determination after reviewing your complete medical history and lab results.
Patients who are NOT good candidates for GLP-1 medications include those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, those with a history of pancreatitis, patients who are pregnant or planning to become pregnant, and patients with certain gastrointestinal conditions. Your Enhance MD physician will screen for all of these during the consultation process.
Beyond clinical eligibility, Enhance MD is particularly well suited for patients who have insurance coverage and want to maximize the medical oversight they receive, patients with complex health histories who need careful physician assessment before starting medication, and patients who have tried other weight loss approaches without sustained success and want a medically comprehensive program.
Enhance MD uses transparent all-inclusive pricing — meaning the monthly fee covers physician oversight, lab coordination, and medication without surprise add-on costs. The exact pricing should be verified directly on their site as GLP-1 program pricing across the telehealth industry has been volatile following the 2025–2026 regulatory changes around compounding.
For patients with insurance, it is worth asking Enhance MD directly about their insurance coordination process. Some GLP-1 programs for obesity are covered under commercial insurance plans, particularly following the expansion of obesity treatment coverage by many insurers in 2024–2025. Your physician can provide documentation supporting a prior authorization request if your insurer requires one.
💡 Cost tip: If you have insurance, ask Enhance MD about prior authorization support before assuming you will be paying out of pocket. Branded GLP-1 medications for obesity have seen significant expansion in insurance coverage and the monthly cost with insurance can be substantially lower than the out-of-pocket list price.
| Criteria | Enhance MD | Direct Meds | Sprout Health |
|---|---|---|---|
| Physician oversight | ✓ Every Rx | ✓ Licensed MDs | ✓ Every Rx |
| Lab testing included | ✓ Yes | Verify at site | Verify at site |
| GIP-GLP-1 access | ✓ Yes | GLP-1 only | GLP-1 only |
| Approval speed | Thorough | Fast | Streamlined |
| Best for | Medical supervision | Fast approval | Nationwide access |
Enhance MD is our top-rated program for patients who want the most comprehensive, physician-supervised GLP-1 treatment available through a telehealth platform. The inclusion of lab testing, access to both GLP-1 and GIP-GLP-1 medications, and genuine physician oversight throughout the treatment journey set them apart from the majority of telehealth competitors. If you are insured, have a complex health history, or simply want the highest standard of medical care in your GLP-1 program, Enhance MD is the strongest option in our current directory. If your priority is speed or you are self-pay and cost-sensitive, Direct Meds or Sprout Health may be more practical starting points.
Check current pricing, confirm state availability, and start your physician consultation on the Enhance MD platform.
Visit Enhance MD →⚠️ Affiliate Disclosure: Paragon Health Access is operated by Paragon Frontier Capital LLC and earns a commission if you enroll through this link. This does not affect the price you pay or our editorial assessment. All medical decisions are made by licensed Enhance MD physicians. This is not medical advice. Last reviewed May 2026 — verify all program details directly before enrolling.